Anti-HIV Drugs | Oscar Miranda | Sunday | Sunday

Third floor of a building in the urbanization of Santa Luz Mira, commais one of the mildest scenarios in which Peru begins to win the fight against the epidemic since August 2 last year. HIV AIDS.

In this space is the integrated care module sexually transmitted infection Director of the Maternal and Child Health Center of Mira II in St. Luz. One of 10 places selected by the Ministry of Health (Minsa) began offering free pre-exposure prophylaxis. The prestigious and long-awaited foundation course.

PreP, a treatment consisting of tablets of two antiretroviral drugs (emtricitabine and tenofovir), can reduce the chance of contracting HIV by up to 92% if taken daily.

    This drug combines two antiretroviral drugs: emtricitabine and tenofovir. Photo: Marcos Cotrina/La República

This drug combines two antiretroviral drugs: emtricitabine and tenofovir. Photo: Marcos Cotrina/La República

It was originally produced by North American laboratory Gilead Sciences and marketed under the name Truvada as an antiretroviral drug for HIV-positive people until it was found in 2012 to be very effective in preventing infection as well.

For years, governments around the world have begun distributing the drug for free, especially to those deemed at high risk of infection: men who have sex with men, transgender women and sex workers. In Latin America, Brazil, Argentina and Chile are countries following this example.

Source link

Leave a Comment